These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 36428587)

  • 1. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.
    Hasselbalch H; Skov V; Kjær L; Larsen MK; Knudsen TA; Lucijanić M; Kusec R
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch HC; Holmström MO
    Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons in the treatment of myeloproliferative neoplasms.
    Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S
    Ther Adv Hematol; 2024; 15():20406207241229588. PubMed ID: 38380373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
    Bjørn ME; Hasselbalch HC
    Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hasselbalch HC
    Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
    Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
    Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.
    How J; Hobbs G
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
    Hu JK; Carlson K; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):41-44. PubMed ID: 32226334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
    Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
    Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.
    Utke Rank C; Weis Bjerrum O; Larsen TS; Kjær L; de Stricker K; Riley CH; Hasselbalch HC
    Leuk Lymphoma; 2016 Feb; 57(2):348-354. PubMed ID: 25956046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
    Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
    Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.
    Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Ellervik C; Larsen MK; Kjaer L; Skov V; Hasselbalch HC; Ottesen JT
    Cancer Med; 2023 Feb; 12(4):4218-4226. PubMed ID: 36254099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
    Gilbert HS
    Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
    Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
    Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World.
    Sun Y; Cai Y; Cen J; Zhu M; Pan J; Wang Q; Wu D; Chen S
    Front Oncol; 2021; 11():797825. PubMed ID: 34993148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
    Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
    [No Abstract]   [Full Text] [Related]  

  • 19. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
    Khodier M; Gadó K
    Physiol Int; 2023 Sep; 110(3):227-250. PubMed ID: 37651280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.